Table 1. Clinical, echocardiographic and procedural characteristic of the study population.

	Study population	PAF	PersAF
	n = 80	n = 34	n = 46
Age, years	62±10	60±11	63±10
Males, %	62	62	65
Paroxysmal AF, %	41
Re-do, %	35	38	35
RR systolic, mmHg	144±22	141±33	141±18
RR diastolic, mmHg	84±13	82±10	84±14
Heart rate, bpm	79±22	71±20	86±20
BMI, (kg/m2)	30±6	29±7	30±5
eGFR, ml/min/1.73 m2	97±31	96±28	99±34
Medical history, %
Hypertension	85	77	89
Diabetes mellitus	19	9	26
Vascular disease	29	18	37
Previous TE	8	9	7
CHADS2 score	1 [1]–[2]	1 [1]–[2]	1 [1]–[2]
CHA2DS2-VASc score	2 [1]–[3]	2 [1]–[3]	3 [2]–[4]
Medical treatment, %
Beta blockers	85	82	87
ACEI/ARB	63	50	74
Statins	34	21	41
Anticoagulation, %
VKA	58	50	65
NOACs	28	24	33
Echocardiographic data
LAD, mm	44±6	41±6	46±6
LV-EDd, mm	51±6	49±6	52±8
EF, %	56±10	59±8	54±10
Procedural data
Substrate modification, %	32	18	46
CTI, %	27	21	28
Low voltage areals, %	34	27	41
CV during procedure, %	61	38	78
Heparin, total, IU	13,253±3,152	12,382±3,257	13,957±3,049
First ACT	268±60	259±56	271±67
ACT at the end of procedure	285±49	282±54	287±45
Ablation time, s	1,688 [1103–2,704]	1,278 [962–2,004]	2,109 [1,398–2,843]
Total ablation power, J	56,616 [39,009–90,262]	45,414 [35,061–61,952]	72,769 [44,587–93,872]
Procedure time, min	150 [120–213]	120 [106–175]	180 [148–233]

Abbreviations: BMI – body mass index; TE - thromboembolic events, VKA – vitamin K antagonists; ACEI – angiotensin converting enzyme inhibitors; ARB – angiotensin receptor blockers; non-OAC – anticoagulation with aspirin, clopidogrel or low molecular weight heparins, LAD – left atrial diameter, IVSd – interventricular septum end-diatolic, LV-EDd – left ventricular end-diastolic diameter, EF – ejection fraction, LAA – left atrial appendage, SR – sinus rhythm, CV – electrical cardioversion, ACT – activated clotting time.

Data mean ± SD, median [interquartile range], or actual numbers/%.